用于胶质瘤预测与诊断生物标志物识别的定制RNA测序面板开发
本研究用定制RNA测序面板TOP2-RNA检测124例恶性胶质瘤冷冻样本,以分子分型并寻找分子靶点。55例胶质母细胞瘤中11例(20%)检出基因融合,15例(27.3%)有酪氨酸激酶基因过表达;IDH突变肿瘤几乎无融合或过表达。TOP2-RNA可高灵敏检测融合基因、外显子跳跃和异常表达。
要点
- TOP2-RNA可高灵敏检测融合基因、外显子跳跃和异常基因表达。
- 55例胶质母细胞瘤中11例(20%)检出基因融合,包括新发现的MET融合。
- 55例胶质母细胞瘤中15例(27.3%)有7个酪氨酸激酶基因过表达。
核心结论
- TOP2-RNA是检测融合基因、外显子跳跃和异常基因表达的高灵敏方法。
- 超过50%的胶质母细胞瘤中可识别可靶向的驱动基因改变。
- TOP2-RNA分子分型可提供常规方法可能无法识别的预测、预后和诊断生物标志物,有望增加胶质瘤患者的治疗选择。
研究设计与样本
- 采用定制靶向RNA测序面板Todai OncoPanel 2 RNA Panel(TOP2-RNA),使用连接捕获法以最大化检测455个融合基因转录本的灵敏度,并分析1,390个基因的表达谱。
- 对124例恶性胶质瘤冷冻样本进行TOP2-RNA检测,基于分子谱进行分型并识别分子靶点。
主要发现
- 55例胶质母细胞瘤中,11例(20%)检出基因融合,包括新发现的MET融合;15例(27.3%)有7个酪氨酸激酶基因过表达。
- 与IDH野生型胶质母细胞瘤不同,IDH突变肿瘤(包括星形细胞瘤和少突胶质细胞瘤)几乎不携带融合基因或基因过表达。
- 34个过表达的酪氨酸激酶基因中,胶质母细胞瘤的MDM2和CDK4观察到22例拷贝数扩增(64.7%)。
- 基因集富集分析比较星形细胞瘤与少突胶质细胞瘤时,与1p36和19q相关的基因集在星形细胞瘤中高度富集,提示基因表达分析可评估区域基因组DNA拷贝数改变。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Various molecular profiles are needed to classify malignant brain tumors, including gliomas, based on the latest classification criteria of the World Health Organization, and their poor prognosis necessitates new therapeutic targets. The Todai OncoPanel 2 RNA Panel (TOP2-RNA) is a custom-target RNA-sequencing (RNA-seq) using the junction capture method to maximize the sensitivity of detecting 455 fusion gene transcripts and analyze the expression profiles of 1,390 genes. This study aimed to classify gliomas and identify their molecular targets using TOP2-RNA. METHODS: A total of 124 frozen samples of malignant gliomas were subjected to TOP2-RNA for classification based on their molecular profiles and the identification of molecular targets. RESULTS: Among 55 glioblastoma cases, gene fusions were detected in 11 cases (20%), including novel MET fusions. Seven tyrosine kinase genes were found to be overexpressed in 15 cases (27.3%). In contrast to isocitrate dehydrogenase (IDH) wild-type glioblastoma, IDH-mutant tumors, including astrocytomas and oligodendrogliomas, barely harbor fusion genes or gene overexpression. Of the 34 overexpressed tyrosine kinase genes, MDM2 and CDK4 in glioblastoma, 22 copy number amplifications (64.7%) were observed. When comparing astrocytomas and oligodendrogliomas in gene set enrichment analysis, the gene sets related to 1p36 and 19q were highly enriched in astrocytomas, suggesting that regional genomic DNA copy number alterations can be evaluated by gene expression analysis. CONCLUSIONS: TOP2-RNA is a highly sensitive assay for detecting fusion genes, exon skipping, and aberrant gene expression. Alterations in targetable driver genes were identified in more than 50% of glioblastoma. Molecular profiling by TOP2-RNA provides ample predictive, prognostic, and diagnostic biomarkers that may not be identified by conventional assays and, therefore, is expected to increase treatment options for individual patients with glioma.
引用
- Shirai Y, Ueno T, Kojima S, et al. The development of a custom RNA-sequencing panel for the identification of predictive and diagnostic biomarkers in glioma. J Neurooncol. 2024. PMID: 38363490. doi:10.1007/s11060-024-04563-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。